PubRank

Steven A Feldman

Author PubWeight™ 55.05‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol 2011 9.19
2 B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 2011 8.26
3 Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 2010 7.25
4 Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J Immunother 2013 4.80
5 Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. Blood 2013 3.45
6 T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol Ther 2010 3.29
7 Single and dual amino acid substitutions in TCR CDRs can enhance antigen-specific T cell functions. J Immunol 2008 2.54
8 Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor. J Immunother 2009 2.35
9 Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma. Hum Gene Ther 2012 1.75
10 Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice. J Clin Invest 2010 1.53
11 A TCR targeting the HLA-A*0201-restricted epitope of MAGE-A3 recognizes multiple epitopes of the MAGE-A antigen superfamily in several types of cancer. J Immunol 2010 1.45
12 A novel chimeric antigen receptor against prostate stem cell antigen mediates tumor destruction in a humanized mouse model of pancreatic cancer. Hum Gene Ther 2014 1.05
13 A high molecular weight melanoma-associated antigen-specific chimeric antigen receptor redirects lymphocytes to target human melanomas. Cancer Res 2010 1.02
14 Identification of linear heparin-binding peptides derived from human respiratory syncytial virus fusion glycoprotein that inhibit infectivity. J Virol 2006 1.01
15 Development of a genetically-modified novel T-cell receptor for adoptive cell transfer against renal cell carcinoma. J Immunol Methods 2011 0.95
16 Replication-competent retroviruses in gene-modified T cells used in clinical trials: is it time to revise the testing requirements? Mol Ther 2012 0.94
17 Enhanced receptor expression and in vitro effector function of a murine-human hybrid MART-1-reactive T cell receptor following a rapid expansion. Cancer Immunol Immunother 2010 0.92
18 Evaluation of γ-retroviral vectors that mediate the inducible expression of IL-12 for clinical application. J Immunother 2012 0.85
19 Augmented lymphocyte expansion from solid tumors with engineered cells for costimulatory enhancement. J Immunother 2011 0.81
20 A novel murine T-cell receptor targeting NY-ESO-1. J Immunother 2014 0.81
21 A simple and effective method to generate lentiviral vectors for ex vivo gene delivery to mature human peripheral blood lymphocytes. Hum Gene Ther Methods 2012 0.80
22 Host range and receptor binding properties of vectors bearing feline leukemia virus subgroup B envelopes can be modulated by envelope sequences outside of the receptor binding domain. J Virol 2002 0.78
23 Confessions of a managed behavioral health care physician. J Dev Behav Pediatr 2002 0.77
24 Isolation and Characterization of an HLA-DPB1*04: 01-restricted MAGE-A3 T-Cell Receptor for Cancer Immunotherapy. J Immunother 2016 0.75